News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
336,495 Results
Type
Article (20177)
Company Profile (129)
Press Release (316189)
Multimedia
Podcasts (75)
Webinars (11)
Section
Business (105986)
Career Advice (883)
Deals (18635)
Drug Delivery (98)
Drug Development (50872)
Employer Resources (79)
FDA (7746)
Job Trends (7816)
News (186783)
Policy (17435)
Tag
Academia (742)
Accelerated approval (3)
Adcomms (17)
Allergies (46)
Alliances (28072)
ALS (57)
Alzheimer's disease (643)
Antibody-drug conjugate (ADC) (102)
Approvals (7756)
Artificial intelligence (153)
Autoimmune disease (17)
Automation (6)
Bankruptcy (177)
Best Places to Work (5609)
BIOSECURE Act (13)
Biosimilars (99)
Biotechnology (57)
Bladder cancer (42)
Brain cancer (19)
Breast cancer (116)
Cancer (1144)
Cardiovascular disease (118)
Career advice (717)
Career pathing (21)
CAR-T (56)
Cell therapy (161)
Cervical cancer (6)
Clinical research (42867)
Collaboration (504)
Compensation (189)
Complete response letters (23)
COVID-19 (1106)
CRISPR (27)
C-suite (166)
Cystic fibrosis (60)
Data (1247)
Decentralized trials (2)
Denatured (19)
Depression (27)
Diabetes (149)
Diagnostics (1834)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (82)
Drug pricing (116)
Drug shortages (30)
Duchenne muscular dystrophy (63)
Earnings (39464)
Editorial (34)
Employer branding (10)
Employer resources (73)
Events (49065)
Executive appointments (480)
FDA (8435)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (336)
Gene editing (54)
Generative AI (18)
Gene therapy (154)
GLP-1 (610)
Government (1876)
Grass and pollen (3)
Guidances (77)
Healthcare (5949)
Huntington's disease (15)
IgA nephropathy (21)
Immunology and inflammation (92)
Indications (19)
Infectious disease (1188)
Inflammatory bowel disease (90)
Inflation Reduction Act (8)
Influenza (25)
Intellectual property (58)
Interviews (116)
IPO (7412)
IRA (45)
Job creations (2439)
Job search strategy (650)
Kidney cancer (7)
Labor market (29)
Layoffs (287)
Leadership (16)
Legal (4126)
Liver cancer (32)
Lung cancer (171)
Lymphoma (93)
Machine learning (5)
Management (30)
Manufacturing (233)
MASH (54)
Medical device (2051)
Medtech (2054)
Mergers & acquisitions (11502)
Metabolic disorders (524)
Multiple sclerosis (50)
NASH (20)
Neurodegenerative disease (52)
Neuropsychiatric disorders (23)
Neuroscience (979)
NextGen: Class of 2025 (2382)
Non-profit (917)
Now hiring (24)
Obesity (328)
Opinion (191)
Ovarian cancer (35)
Pain (77)
Pancreatic cancer (42)
Parkinson's disease (87)
Partnered (12)
Patents (156)
Patient recruitment (51)
Peanut (16)
People (33770)
Pharmaceutical (74)
Pharmacy benefit managers (22)
Phase I (13420)
Phase II (18131)
Phase III (14575)
Pipeline (855)
Policy (133)
Postmarket research (1622)
Preclinical (4711)
Press Release (30)
Prostate cancer (65)
Psychedelics (16)
Radiopharmaceuticals (162)
Rare diseases (255)
Real estate (3194)
Recruiting (29)
Regulatory (12680)
Reports (23)
Research institute (829)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (2)
RSV (25)
Schizophrenia (63)
Series A (60)
Series B (37)
Service/supplier (7)
Sickle cell disease (38)
Special edition (16)
Spinal muscular atrophy (111)
Sponsored (12)
Startups (2021)
State (2)
Stomach cancer (9)
Supply chain (55)
Tariffs (51)
The Weekly (54)
Vaccines (290)
Venture capitalists (30)
Weight loss (247)
Women's health (14)
Worklife (8)
Date
Last 7 days (486)
Last 30 days (1476)
Last 365 days (16560)
2025 (6063)
2024 (17778)
2023 (19742)
2022 (25975)
2021 (26803)
2020 (25054)
2019 (20229)
2018 (15717)
2017 (17351)
2016 (16261)
2015 (18868)
2014 (14853)
2013 (12612)
2012 (13562)
2011 (13896)
2010 (12794)
Location
Africa (409)
Alabama (24)
Alaska (1)
Arizona (68)
Arkansas (8)
Asia (25040)
Australia (3238)
California (2750)
Canada (1171)
China (351)
Colorado (107)
Connecticut (105)
Delaware (81)
Europe (51809)
Florida (488)
Georgia (59)
Idaho (16)
Illinois (265)
India (20)
Indiana (181)
Iowa (3)
Japan (132)
Kansas (65)
Kentucky (18)
Louisiana (3)
Maine (4)
Maryland (398)
Massachusetts (2319)
Michigan (49)
Minnesota (145)
Mississippi (1)
Missouri (28)
Montana (10)
Nebraska (11)
Nevada (19)
New Hampshire (8)
New Jersey (1106)
New Mexico (21)
New York (807)
North Carolina (538)
North Dakota (2)
Northern California (1175)
Ohio (88)
Oklahoma (5)
Oregon (21)
Pennsylvania (658)
Puerto Rico (12)
Rhode Island (19)
South America (611)
South Carolina (4)
Southern California (1124)
Tennessee (41)
Texas (362)
United States (10981)
Utah (60)
Virginia (94)
Washington D.C. (48)
Washington State (232)
Wisconsin (25)
336,495 Results for "lifecycle pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
Compensation
Top 6 Highest-Paid Pharma CEOs in 2024
Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.
April 16, 2025
·
7 min read
·
Annalee Armstrong
Europe
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission
Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a smoother regulatory framework.
April 16, 2025
·
2 min read
·
Tristan Manalac
Deals
M&A, IPOs Snarled by Policy Reality in Q1 as Pharmas Opt for Licensing Deals
M&A and IPOs got off to a quick start in 2025 only to crash into a wall of policy challenges. Upfront payment for licensing transactions, however, grew as pharmas looked for less-risky deals.
May 7, 2025
·
3 min read
·
Annalee Armstrong
Tariffs
Trump Opens National Security Probe on Pharma Imports, Signaling Imminent Tariffs
Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.
April 15, 2025
·
2 min read
·
Tristan Manalac
Business
Five Biggest Drug Face-Offs in Pharma History
Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis.
April 9, 2025
·
9 min read
·
Tristan Manalac
Tariffs
Trump Tariff Pause Sparks Late-Day Rally for Pharma Stocks—But Not All
Pharma stocks went on a wild ride Wednesday amid whiplashing tariff threats from the U.S. president.
April 10, 2025
·
2 min read
·
Annalee Armstrong
Clinical research
Pharma R&D Returns Grow Again, But Deloitte Warns Progress is ‘Fragile’
Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.
March 27, 2025
·
3 min read
·
Annalee Armstrong
Tariffs
J&J CEO Duato Urges Tax Fix, Not Tariffs To Drive US Pharma Manufacturing
In the company’s first-quarter earnings call Tuesday, J&J CEO Joaquin Duato said there’s a better way to encourage drug manufacturing in the U.S. than President Donald Trump’s threatened pharma tariffs.
April 15, 2025
·
3 min read
·
Annalee Armstrong
Government
Trump Threatens Big Pharma With Tariffs—Unless They Reshore Manufacturing: Bloomberg
President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.
February 24, 2025
·
2 min read
·
Tristan Manalac
1 of 33,650
Next
